# Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

> **NCT01310881** · PHASE1 · COMPLETED · sponsor: **Neuralstem Inc.** · enrollment: 35 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** NSI-189 Phosphate

## Key facts

- **NCT ID:** NCT01310881
- **Lead sponsor:** Neuralstem Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2011-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310881, "Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01310881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*